adhesion G protein-coupled receptor G3Genealiases: GPR97 · PB99 · PGR26
Q-omics provides the consensus-scored ADGRG3 profile across patient tissues and cancer cell-line models. ADGRG3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADGRG3 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ADGRG3 RNA expression shows 23,379 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, THCA, and PDAC as cancer lineages where ADGRG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRG3 survival associations across molecular data types. ADGRG3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRG3 RNA expression–survival associations across cancer types. High ADGRG3 expression shows unfavorable associations in KIRC, LIHC, LUAD and UVM, but favorable associations in UCS and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ADGRG3 RNA expression.
This table summarizes ADGRG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ADGRG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRG3 shows lower tumor expression in THCA, BRCA and UCEC and higher tumor expression in KIRC, HNSC and CHOL. The THCA box plot shows higher ADGRG3 RNA expression in normal versus tumor tissue (log2 FC = −1.224, t-test p < 0.001).
This table shows molecular features associated with ADGRG3 in patient tissues and cancer cell lines. In patient samples, ADGRG3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
